



NEW ZEALAND'S EXCHANGE  
TE PAEHOKO O AOTEAROA

# Template Capital Change Notice

Updated as at 17 October 2019

Section 1: Issuer information	
Name of issuer	Vital Limited
NZX ticker code	VTL
Class of financial product	Options to acquire fully paid ordinary share
ISIN (If unknown, check on NZX website)	NZTTKE0001S4
Currency	Not applicable
Section 2: Capital change details	
Number issued/acquired/redeemed	190,000 options issued, each option for one fully paid ordinary share
Nominal value (if any)	Not applicable
Issue/acquisition/redemption price per security	Nil on issue. Exercise price for each option is \$0.32 per fully paid ordinary share.
Nature of the payment (for example, cash or other consideration)	Nil on issue. The exercise price is payable in cash
Amount paid up (if not in full)	Not applicable
Percentage of total class of Financial Products issued/acquired/redeemed/ (calculated on the number of Financial Products of the Class, excluding any Treasury Stock, in existence) <sup>1</sup>	0.457% Calculation based on the total number of ordinary shares in existence immediately prior to the issue of the options.
For an issue of Convertible Financial Products or Options, the principal terms of Conversion (for example the Conversion price and Conversion date and the ranking of the Financial Product in relation to other Classes of Financial Product) or the Option (for example, the exercise price and exercise date)	Each option has an exercise price of \$0.32. The terms of each option are as set out in the VTL Employee Share Option Plan (which is embodied in a Share Option Deed entered into with the relevant participant. The options may be exercised by the participant (in whole or part) in the period from 3-years to 4.5 years from the date granted (early conversion allowed in some circumstances such as Company takeover). The key employee must be employed by Vital at the time of exercise and has an 18-month window to exercise from the first exercise date.

<sup>1</sup> The percentage is to be calculated immediately before the issue, acquisition, redemption or Conversion.

Reason for issue/ <del>acquisition/redemption</del> and specific authority for issue/acquisition/redemption/ (the reason for change must be identified here)	Issue of options to senior managers pursuant to Vitals' ESOP programme and as approved by the Directors.
Total number of Financial Products of the Class after the issue/ <del>acquisition/redemption/Conversion</del> (excluding Treasury Stock) and the total number of Financial Products of the Class held as Treasury Stock after the issue/acquisition/redemption.	42,688,318 This is made up of 41,548,318 ordinary shares and two tranches of ESOP options which when exercised will enable the holders to acquire 1,140,000 ordinary shares.
In the case of an acquisition of shares, whether those shares are to be held as treasury stock	Not applicable.
Specific authority for the issue, acquisition, or redemption, including a reference to the rule pursuant to which the issue, acquisition, or redemption is made	Board resolution for the purposes of Listing Rule 4.6.
Terms or details of the issue, acquisition, or redemption (for example: restrictions, escrow arrangements)	As set out above.
Date of issue/ <del>acquisition/redemption</del> <sup>2</sup>	04/03/2024
<b>Section 3: Authority for this announcement and contact person</b>	
Name of person authorised to make this announcement	John McMahon
Contact person for this announcement	John McMahon
Contact phone number	+64 (0)21 0914 0236
Contact email address	John.mcmahon@auroinvest.com
Date of release through MAP	07/03/2024

---

<sup>2</sup> Continuous issuers using this form in reliance on Rule 3.13.2, please indicate the period during which the relevant issue/acquisition/redemptions were made (for example, 1 January 2019 to 31 January 2019).